Modulation by Neuropeptide FF of the interaction of Mu-opioid (MOP) receptor with G-proteins

Neurochemistry International

Volumn 56, Issue 6-7, 2010, Pages 768-773

  Kersanté, Flavie ^a   Moulédous, Lionel ^a   Zajac, Jean Marie ^a   Mollereau, Catherine ^a  

^a UNIVERSITÉ DE TOULOUSE   (France)

Author keywords

35S GTP S binding; Dimerization; G protein; Neuropeptide FF receptor; Opioid receptor

Indexed keywords

ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANINE NUCLEOTIDE BINDING PROTEIN GAMMA SUBUNIT; MU OPIATE RECEPTOR; NEUROPEPTIDE FF; NEUROPEPTIDE FF AGONIST; NEUROPEPTIDE FF2 RECEPTOR; NEUROPEPTIDE RECEPTOR; OPIATE AGONIST; UNCLASSIFIED DRUG;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; NEUROBLASTOMA CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN PROTEIN INTERACTION; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANALGESICS, OPIOID; CELL LINE; CELL LINE, TUMOR; ENKEPHALIN, ALA(2)-MEPHE(4)-GLY(5)-; GENE EXPRESSION; GTP-BINDING PROTEINS; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); HUMANS; IMMUNOSORBENT TECHNIQUES; NARCOTIC ANTAGONISTS; NEUROBLASTOMA; OLIGOPEPTIDES; RECEPTORS, NEUROPEPTIDE; RECEPTORS, OPIOID, MU; SULFUR RADIOISOTOPES; TRANSFECTION;

EID: 77952265056     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuint.2010.02.014     Document Type: Article

References (52)

1. Alt A., Clark M.J., Woods J.H., Traynor J.R. Mu and Delta opioid receptors activate the same G proteins in human neuroblastoma SH-SY5Y cells. Br. J. Pharmacol. 2002, 135(1):217-225.
2. Bonini J.A., Jones K.A., Adham N., Forray C., Artymyshyn R., Durkin M.M., Smith K.E., Tamm J.A., Boteju L.W., Lakhlani P.P., Raddatz R., Yao W.J., Ogozalek K.L., Boyle N., Kouranova E.V., Quan Y., Vaysse P.J., Wetzel J.M., Branchek T.A., Gerald C., Borowsky B. Identification and characterization of two G protein-coupled receptors for Neuropeptide FF. J. Biol. Chem. 2000, 275(50):39324-39331.
3. Carter B.D., Medzihradsky F. Go mediates the coupling of the mu opioid receptor to adenylyl cyclase in cloned neural cells and brain. Proc. Natl. Acad. Sci. U.S.A. 1993, 90(9):4062-4066.
4. Chakrabarti S., Regec A., Gintzler A.R. Biochemical demonstration of mu-opioid receptor association with Gsalpha: enhancement following morphine exposure. Brain Res. Mol. Brain Res. 2005, 135(1-2):217-224.
5. Chalecka-Franaszek E., Weems H.B., Crowder A.T., Cox B.M., Cote T.E. Immunoprecipitation of high-affinity, guanine nucleotide-sensitive, solubilized mu-opioid receptors from rat brain: coimmunoprecipitation of the G proteins G(alpha o), G(alpha i1), and G(alpha i3). J. Neurochem. 2000, 74(3):1068-1078.
6. Chen C., Li J., Bot G., Szabo I., Rogers T.J., Liu-Chen L.Y. Heterodimerization and cross-desensitization between the mu-opioid receptor and the chemokine CCR5 receptor. Eur. J. Pharmacol. 2004, 483(2-3):175-186.
7. Crain S.M., Shen K.F. Modulatory effects of Gs-coupled excitatory opioid receptor functions on opioid analgesia, tolerance, and dependence. Neurochem. Res. 1996, 21(11):1347-1351.
8. George S.R., Fan T., Xie Z., Tse R., Tam V., Varghese G., O'Dowd B.F. Oligomerization of mu- and delta-opioid receptors. Generation of novel functional properties. J. Biol. Chem. 2000, 275(34):26128-26135.
9. Gicquel S., Mazarguil H., Allard M., Simonnet G., Zajac J.M. Analogues of F8Famide resistant to degradation, with high affinity and in vivo effects. Eur. J. Pharmacol. 1992, 222(1):61-67.
10. Gintzler A.R., Chakrabarti S. Post-opioid receptor adaptations to chronic morphine; altered functionality and associations of signaling molecules. Life Sci. 2006, 79(8):717-722.
11. Gintzler A.R., Chakrabarti S. The ambiguities of opioid tolerance mechanisms: barriers to pain therapeutics or new pain therapeutic possibilities. J. Pharmacol. Exp. Ther. 2008, 325(3):709-713.
12. Gomes I., Gupta A., Filipovska J., Szeto H.H., Pintar J.E., Devi L.A. A role for heterodimerization of mu and delta opiate receptors in enhancing morphine analgesia. Proc. Natl. Acad. Sci. U.S.A. 2004, 101(14):5135-5139.
13. Gomes I., Jordan B.A., Gupta A., Trapaidze N., Nagy V., Devi L.A. Heterodimerization of mu and delta opioid receptors: a role in opiate synergy. J. Neurosci. 2000, 20(22):RC110.
14. 35S]GTPgammaS binding. Neuropharmacology 2007, 52(2):376-386.
15. Gouarderes C., Zajac J.M. Biochemical anti-opioid action of NPFF2 receptors in rat spinal cord. Neurosci. Res. 2007, 58(1):91-94.
16. Gupta A., Decaillot F.M., Devi L.A. Targeting opioid receptor heterodimers: strategies for screening and drug development. AAPS J. 2006, 8(1):E153-159.
17. 35S]GTPgammaS binding assay: approaches and applications in pharmacology. Life Sci. 2003, 74(4):489-508.
18. Harrison L.M., Kastin A.J., Zadina J.E. Opiate tolerance and dependence: receptors, G-proteins, and antiopiates. Peptides 1998, 19(9):1603-1630.
19. Hinuma S., Shintani Y., Fukusumi S., Iijima N., Matsumoto Y., Hosoya M., Fujii R., Watanabe T., Kikuchi K., Terao Y., Yano T., Yamamoto T., Kawamata Y., Habata Y., Asada M., Kitada C., Kurokawa T., Onda H., Nishimura O., Tanaka M., Ibata Y., Fujino M. New neuropeptides containing carboxy-terminal RFamide and their receptor in mammals. Nat. Cell Biol. 2000, 2(10):703-708.
20. Jordan B.A., Gomes I., Rios C., Filipovska J., Devi L.A. Functional interactions between mu opioid and alpha 2A-adrenergic receptors. Mol. Pharmacol. 2003, 64(6):1317-1324.
21. Kathmann M., Flau K., Redmer A., Trankle C., Schlicker E. Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors. Naunyn Schmiedebergs Arch. Pharmacol. 2006, 372(5):354-361.
22. Kersanté F., Mollereau C., Zajac J.M., Roumy M. Anti-opioid activities of NPFF(1) receptors in a SH-SY5Y model. Peptides 2006, 27(5):980-989.
23. Largent-Milnes T.M., Guo W., Wang H.Y., Burns L.H., Vanderah T.W. Oxycodone plus ultra-low-dose naltrexone attenuates neuropathic pain and associated mu-opioid receptor-Gs coupling. J. Pain 2008, 9(8):700-713.
24. Laugwitz K.L., Offermanns S., Spicher K., Schultz G. mu and delta opioid receptors differentially couple to G protein subtypes in membranes of human neuroblastoma SH-SY5Y cells. Neuron 1993, 10(2):233-242.
25. Mazarguil H., Gouarderes C., Tafani J.A., Marcus D., Kotani M., Mollereau C., Roumy M., Zajac J.M. Structure-activity relationships of Neuropeptide FF: role of C-terminal regions. Peptides 2001, 22(9):1471-1478.
26. 35S]GTP gamma S binding assays. Trends Pharmacol. Sci. 2003, 24(2):87-90.
27. Mollereau C., Mazarguil H., Zajac J.M., Roumy M. Neuropeptide FF (NPFF) analogs functionally antagonize opioid activities in NPFF2 receptor-transfected SH-SY5Y neuroblastoma cells. Mol. Pharmacol. 2005, 67(3):965-975.
28. Mollereau C., Roumy M., Zajac J.M. Opioid-modulating peptides: mechanisms of action. Curr. Top. Med. Chem. 2005, 5(3):341-355.
29. Moulédous L., Merker S., Neasta J., Roux B., Zajac J.M., Mollereau C. Neuropeptide FF-sensitive confinement of mu opioid receptor does not involve lipid rafts in SH-SY5Y cells. Biochem. Biophys. Res. Commun. 2008, 373(1):80-84.
30. Ocana M., Cendan C.M., Cobos E.J., Entrena J.M., Baeyens J.M. Potassium channels and pain: present realities and future opportunities. Eur. J. Pharmacol. 2004, 500(1-3):203-219.
31. Pan H.L., Wu Z.Z., Zhou H.Y., Chen S.R., Zhang H.M., Li D.P. Modulation of pain transmission by G-protein-coupled receptors. Pharmacol. Ther. 2008, 117(1):141-161.
32. Panula P., Kalso E., Nieminen M., Kontinen V.K., Brandt A., Pertovaara A. Neuropeptide FF and modulation of pain. Brain Res. 1999, 848(1-2):191-196.
33. Perry S.J., Yi-Kung Huang E., Cronk D., Bagust J., Sharma R., Walker R.J., Wilson S., Burke J.F. A human gene encoding morphine modulating peptides related to NPFF and FMRFamide. FEBS Lett. 1997, 409(3):426-430.
34. Pfeiffer M., Kirscht S., Stumm R., Koch T., Wu D., Laugsch M., Schroder H., Hollt V., Schulz S. Heterodimerization of substance P and mu-opioid receptors regulates receptor trafficking and resensitization. J. Biol. Chem. 2003, 278(51):51630-51637.
35. Pfeiffer M., Koch T., Schroder H., Laugsch M., Hollt V., Schulz S. Heterodimerization of somatostatin and opioid receptors cross-modulates phosphorylation, internalization, and desensitization. J. Biol. Chem. 2002, 277(22):19762-19772.
36. 2+ channels in rat spinal ganglion neurones. Neuroreport 1996, 7(18):2979-2981.
37. Remmers A.E., Clark M.J., Alt A., Medzihradsky F., Woods J.H., Traynor J.R. Activation of G protein by opioid receptors: role of receptor number and G-protein concentration. Eur. J. Pharmacol. 2000, 396(2-3):67-75.
38. Rios C., Gomes I., Devi L.A. mu opioid and CB1 cannabinoid receptor interactions: reciprocal inhibition of receptor signaling and neuritogenesis. Br. J. Pharmacol. 2006, 148(4):387-395.
39. Rothman R.B. A review of the role of anti-opioid peptides in morphine tolerance and dependence. Synapse 1992, 12(2):129-138.
40. Roumy M., Garnier M., Zajac J.M. Neuropeptide FF receptors 1 and 2 exert an anti-opioid activity in acutely dissociated rat dorsal raphe and periventricular hypothalamic neurones. Neurosci. Lett. 2003, 348(3):159-162.
41. Roumy M., Lorenzo C., Mazeres S., Bouchet S., Zajac J.M., Mollereau C. Physical association between Neuropeptide FF and micro-opioid receptors as a possible molecular basis for anti-opioid activity. J. Biol. Chem. 2007, 282(11):8332-8342.
42. Roumy M., Zajac J. Neuropeptide FF selectively attenuates the effects of nociceptin on acutely dissociated neurons of the rat dorsal raphe nucleus. Brain Res. 1999, 845(2):208-214.
43. Roumy M., Zajac J.M. Neuropeptide FF, pain and analgesia. Eur. J. Pharmacol. 1998, 345(1):1-11.
44. Roumy M., Zajac J.M. Neuropeptide FF receptors couple to a cholera toxin-sensitive G-protein in rat dorsal raphe neurones. Eur. J. Pharmacol. 2001, 417(1-2):45-49.
45. Roussin A., Serre F., Gouarderes C., Mazarguil H., Roumy M., Mollereau C., Zajac J.M. Anti-analgesia of a selective NPFF(2) agonist depends on opioid activity. Biochem. Biophys. Res. Commun. 2005, 336(1):197-203.
46. Shapira M., Vogel Z., Sarne Y. Opioid and cannabinoid receptors share a common pool of GTP-binding proteins in cotransfected cells, but not in cells which endogenously coexpress the receptors. Cell. Mol. Neurobiol. 2000, 20(3):291-304.
47. Simonnet G., Rivat C. Opioid-induced hyperalgesia: abnormal or normal pain?. Neuroreport 2003, 14(1):1-7.
48. Wang D., Sun X., Bohn L.M., Sadee W. Opioid receptor homo- and heterodimerization in living cells by quantitative bioluminescence resonance energy transfer. Mol. Pharmacol. 2005, 67(6):2173-2184.
49. Wang H.L., Hsu C.Y., Huang P.C., Kuo Y.L., Li A.H., Yeh T.H., Tso A.S., Chen Y.L. Heterodimerization of opioid receptor-like 1 and mu-opioid receptors impairs the potency of micro receptor agonist. J. Neurochem. 2005, 92(6):1285-1294.
50. Wang H.Y., Burns L.H. Gbetagamma that interacts with adenylyl cyclase in opioid tolerance originates from a Gs protein. J. Neurobiol. 2006, 66(12):1302-1310.
51. Wang H.Y., Friedman E., Olmstead M.C., Burns L.H. Ultra-low-dose naloxone suppresses opioid tolerance, dependence and associated changes in mu opioid receptor-G protein coupling and Gbetagamma signaling. Neuroscience 2005, 135(1):247-261.
52. Zajac J.M. Neuropeptide FF: new molecular insights. Trends Pharmacol. Sci. 2001, 22(2):63.